Detalhe da pesquisa
1.
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.
N Engl J Med;
388(7): 595-608, 2023 02 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36791160
2.
Safety and Immunogenicity of a Revaccination With a Respiratory Syncytial Virus Prefusion F Vaccine in Older Adults: A Phase 2b Study.
J Infect Dis;
229(2): 355-366, 2024 Feb 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37699064
3.
Incidence of Cytomegalovirus Primary and Secondary Infection in Adolescent Girls: Results From a Prospective Study.
J Infect Dis;
228(11): 1491-1495, 2023 11 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37340664
4.
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial.
J Infect Dis;
227(6): 761-772, 2023 03 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35904987
5.
Immunogenicity and safety following one dose of AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine in older adults: a phase 3 trial.
J Infect Dis;
2023 Dec 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38099559
6.
A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years.
BMC Infect Dis;
20(1): 426, 2020 Jun 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32552685
7.
Lot-to-lot immunogenicity consistency of the respiratory syncytial virus prefusion F protein vaccine in older adults.
Vaccine X;
18: 100494, 2024 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38746060
8.
Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial.
Respir Investig;
61(2): 261-269, 2023 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36641341
9.
The RSVPreF3-AS01 vaccine elicits broad neutralization of contemporary and antigenically distant respiratory syncytial virus strains.
Sci Transl Med;
15(710): eadg6050, 2023 08 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37611082
10.
Ten-Year Antibody Persistence and Booster Response to MenACWY-TT Vaccine After Primary Vaccination at 1-10 Years of Age.
Hum Vaccin Immunother;
16(6): 1280-1291, 2020 06 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32598244